BioXcel Therapeutics Completes Dosing Two Cohorts of Agitated Schizophrenia Patients with BXCL501 in a Phase 2 Efficacy Trial

June 10, 2019

We're not around right now. But you can send us an email and we'll get back to you, asap.

Start typing and press Enter to search